Abstract
BCR-ABL1 is a fusion tyrosine kinase, which causes multiple types of leukemia. We used an integrated proteomic approach that includes label-free quantitative protein complex and phosphorylation profiling by mass spectrometry to systematically characterize the proximal signaling network of this oncogenic kinase. The proximal BCR-ABL1 signaling network shows a modular and layered organization with an inner core of three leukemia transformation-relevant adaptor protein complexes (Grb2/Gab2/Shc1 complex, CrkI complex and Dok1/Dok2 complex). We introduced an ‘interaction directionality’ analysis, which annotates static protein networks with information on the directionality of phosphorylation-dependent interactions. In this analysis, the observed network structure was consistent with a step-wise phosphorylation-dependent assembly of the Grb2/Gab2/Shc1 and the Dok1/Dok2 complexes on the BCR-ABL1 core. The CrkI complex demonstrated a different directionality, which supports a candidate assembly on the Nedd9 (Hef1, CasL) scaffold. As adaptor protein family members can compensate for each other in leukemic transformation, we compared members of the Dok and Crk protein families and found both overlapping and differential binding patterns. We identified an additional level of regulation for the CrkII protein via binding to 14-3-3 proteins, which was independent from its inhibitory phosphorylation. We also identified novel components of the inner core complexes, including the kinases Pragmin (Sgk223) and Lrrk1 (Lrrk2 paralog). Pragmin was found as a component of the CrkI complex and is a potential link between BCR-ABL1/CrkI and RhoA signaling. Lrrk1 is an unusual kinase with a GTPase domain. We detected Lrrk1 as a component of the Grb2/Gab2/Shc1 complex and found that it functionally interacts with the regulator of small GTPases Arap1 (Centd2) and possibly participates in the mitogen-activated protein kinase response to cellular stresses. This modular and phosphorylation-driven interaction network provides a framework for the integration of pleiotropic signaling effects of BCR-ABL1 toward leukemic transformation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Altun-Gultekin ZF, Chandriani S, Bougeret C, Ishizaki T, Narumiya S, de Graaf P et al. (1998). Activation of Rho-dependent cell spreading and focal adhesion biogenesis by the v-Crk adaptor protein. Mol Cell Biol 18: 3044–3058.
Bache KG, Raiborg C, Mehlum A, Stenmark H . (2003). STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes. J Biol Chem 278: 12513–12521.
Baier T, Neuwirth E . (2009). R (D) COM Server. URL: http://rcom.univie.ac.at/.
Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A et al. (2010). Identification of DOK genes as lung tumor suppressors. Nat Genet 42: 216–223.
Blagoev B, Kratchmarova I, Ong S, Nielsen M, Foster LJ, Mann M . (2003). A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat Biotechnol 21: 315–318.
Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, Köcher T et al. (2009). Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci USA 106: 7414–7419.
Bürckstümmer T, Bennett KL, Preradovic A, Schütze G, Hantschel O, Superti-Furga G et al. (2006). An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat Methods 3: 1013–1019.
Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL . (2005). Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Pro Natl Acad Sci USA 102: 3395–3400.
Caplan AJ, Mandal AK, Theodoraki MA . (2007). Molecular chaperones and protein kinase quality control. Trends Cell Biol 17: 87–92.
Daley GQ, Baltimore D . (1988). Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci USA 85: 9312–9316.
Daniele T, Di Tullio G, Santoro M, Turacchio G, De Matteis MA . (2008). ARAP1 regulates EGF receptor trafficking and signalling. Traffic 9: 2221–2235.
de Jong R, van Wijk A, Haataja L, Heisterkamp N, Groffen J . (1997). BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl. J Biol Chem 272: 32649–32655.
Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, Pear WS et al. (2001). p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med 194: 275–284.
Diella F, Haslam N, Chica C, Budd A, Michael S, Brown NP et al. (2008). Understanding eukaryotic linear motifs and their role in cell signaling and regulation. Front Biosci 13: 6580–6603.
Dosztanyi Z, Csizmok V, Tompa P, Simon I . (2005). IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 21: 3433.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037.
Eck MJ, Dhe-Paganon S, Trüb T, Nolte RT, Shoelson SE . (1996). Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell 85: 695–705.
Faisal A, Kleiner S, Nagamine Y . (2004). Non-redundant role of Shc in Erk activation by cytoskeletal reorganization. J Biol Chem 279: 3202–3211.
Feller SM . (2001). Crk family adaptors-signalling complex formation and biological roles. Oncogene 20: 6348–6371.
Gautreau A, Ho HH, Li J, Steen H, Gygi SP, Kirschner MW . (2004). Purification and architecture of the ubiquitous Wave complex. Proc Natl Acad Sci USA 101: 4379–4383.
Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ et al. (2005). A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365: 415–416.
Gloeckner CJ, Schumacher A, Boldt K, Ueffing M . (2009). The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 109: 959–968.
Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON . (1995). Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82: 981–988.
Goss VL, Lee KA, Moritz A, Nardone J, Spek EJ, MacNeill J et al. (2006). A common phosphotyrosine signature for the Bcr-Abl kinase. Blood 107: 4888–4897.
Goudreault M, D'Ambrosio LM, Kean MJ, Mullin MJ, Larsen BG, Sanchez A et al. (2009). A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. Mol Cell Proteomics 8: 157–171.
Graeber TG, Heath JR, Skaggs BJ, Phelps ME, Remacle F, Levine RD . (2010). Maximal entropy inference of oncogenicity from phosphorylation signaling. Proc Natl Acad Sci USA 107: 6112–6117.
Harada JN, Bower KE, Orth AP, Callaway S, Nelson CG, Laris C et al. (2005). Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis. Genome Res 15: 1136–1144.
Hartwell LH, Hopfield JJ, Leibler S, Murray AW . (1999). From molecular to modular cell biology. Nature 402: C47–C52.
He Y, Wertheim JA, Xu L, Miller JP, Karnell FG, Choi JK et al. (2002). The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 99: 2957–2968.
Hemmeryckx B, Reichert A, Watanabe M, Kaartinen V, de Jong R, Pattengale PK et al. (2002). BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl. Oncogene 21: 3225–3231.
Heo HY, Park J, Kim C, Han BS, Kim K, Seol W . (2010). LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res 316: 649–656.
Hornbeck PV, Chabra I, Kornhauser JM, Skrzypek E, Zhang B . (2004). PhosphoSite: a bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics 4: 1551–1561.
Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D et al. (2004). Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36: 453–461.
Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S . (2006). Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 103: 16870–16875.
Hughan SC, Watson SP . (2007). Differential regulation of adapter proteins Dok2 and Dok1 in platelets, leading to an association of Dok2 with integrin alphaIIbbeta3. J Thromb Haemost 5: 387–394.
Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J et al. (2009). STRING 8—a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37: D412–D416.
Johnson KJ, Griswold IJ, O'Hare T, Corbin AS, Loriaux M, Deininger MW et al. (2009). A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. PLoS ONE 4: e7439.
Kanazawa C, Morita E, Yamada M, Ishii N, Miura S, Asao H et al. (2003). Effects of deficiencies of STAMs and Hrs, mammalian class E Vps proteins, on receptor downregulation. Biochem Biophys Res Commun 309: 848–856.
Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J . (2007). Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13: 1089–1097.
Kerrien S, Alam-Faruque Y, Aranda B, Bancarz I, Bridge A, Derow C et al. (2007). IntAct—open source resource for molecular interaction data. Nucleic Acids Res 35: D561–D565.
Kirsch KH, Georgescu MM, Ishimaru S, Hanafusa H . (1999). CMS: an adapter molecule involved in cytoskeletal rearrangements. Proc Natl Acad Sci USA 96: 6211–6216.
Kobashigawa Y, Sakai M, Naito M, Yokochi M, Kumeta H, Makino Y et al. (2007). Structural basis for the transforming activity of human cancer-related signaling adaptor protein CRK. Nat Struct Mol Biol 14: 503–510.
Korr D, Toschi L, Donner P, Pohlenz H, Kreft B, Weiss B . (2006). LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell Signal 18: 910–920.
Leng Y, Zhang J, Badour K, Arpaia E, Freeman S, Cheung P et al. (2005). Abelson-interactor-1 promotes WAVE2 membrane translocation and Abelson-mediated tyrosine phosphorylation required for WAVE2 activation. Proc Natl Acad Sci USA 102: 1098–1103.
Liou AKF, Leak RK, Li L, Zigmond MJ . (2008). Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol Dis 32: 116–124.
Marchler-Bauer A, Anderson JB, Chitsaz F, Derbyshire MK, DeWeese-Scott C, Fong JH et al. (2009). CDD: specific functional annotation with the Conserved Domain Database. Nucleic Acids Res 37: D205–D210.
McGavin MK, Badour K, Hardy LA, Kubiseski TJ, Zhang J, Siminovitch KA . (2001). The intersectin 2 adaptor links Wiskott Aldrich Syndrome protein (WASp)-mediated actin polymerization to T cell antigen receptor endocytosis. J Exp Med 194: 1777–1787.
Million RP, Van Etten RA . (2000). The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96: 664–670.
Miura K, Jacques KM, Stauffer S, Kubosaki A, Zhu K, Hirsch DS et al. (2002). ARAP1: a point of convergence for Arf and Rho signaling. Mol Cell 9: 109–119.
Morrison DK . (2009). The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 19: 16–23.
Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. (2009). JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 106: 9414–9418.
Neduva V, Russell RB . (2006). Peptides mediating interaction networks: new leads at last. Curr Opin Biotechnol 17: 465–471.
Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW . (1994). Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 84: 2912–2918.
Niki M, Di Cristofano A, Zhao M, Honda H, Hirai H, Van Aelst L et al. (2004). Role of Dok-1 and Dok-2 in leukemia suppression. J Exp Med 200: 1689–1695.
O'Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA . (2007). A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res 67: 8975–8979.
Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ . (1994). Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269: 22925–22928.
Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595–600.
Pawson T . (2007). Dynamic control of signaling by modular adaptor proteins. Curr Opin Cell Biol 19: 112–116.
Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al. (1993). BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75: 175.
Pflieger D, Jünger MA, Müller M, Rinner O, Lee H, Gehrig PM et al. (2008). Quantitative proteomic analysis of protein complexes: concurrent identification of interactors and their state of phosphorylation. Mol Cell Proteomics 7: 326–346.
Prakash A, Mallick P, Whiteaker J, Zhang H, Paulovich A, Flory M et al. (2006). Signal maps for mass spectrometry-based comparative proteomics. Mol Cell Proteomics 5: 423–432.
Prosser DC, Tran D, Gougeon P, Verly C, Ngsee JK . (2008). FFAT rescues VAPA-mediated inhibition of ER-to-Golgi transport and VAPB-mediated ER aggregation. J Cell Sci 121: 3052–3061.
Pui C, Jeha S . (2007). New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 6: 149–165.
R Development Core Team (2009). R: A Language and Environment for Statistical Computing (Vienna, Austria). Available at: http://www.R-project.org.
Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ et al. (2008). Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 26: 3971–3978.
Ramshaw HS, Guthridge MA, Stomski FC, Barry EF, Ooms L, Mitchell CA et al. (2007). The Shc-binding site of the betac subunit of the GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis. Blood 110: 3582–3590.
Ren R . (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5: 172–183.
Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J et al. (2009). LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 29: 9210–9218.
Sämann J, Hegermann J, von Gromoff E, Eimer S, Baumeister R, Schmidt E . (2009). Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem 284: 16482–16491.
Sasaoka T, Ishiki M, Wada T, Hori H, Hirai H, Haruta T et al. (2001). Tyrosine phosphorylation-dependent and -independent role of Shc in the regulation of IGF-1-induced mitogenesis and glycogen synthesis. Endocrinology 142: 5226–5235.
Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. (2002). Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1: 479–492.
Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E et al. (2008). Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14: 485–493.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498–2504.
Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y et al. (2006). Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 103: 19466–19471.
Skehel PA, Fabian-Fine R, Kandel ER . (2000). Mouse VAP33 is associated with the endoplasmic reticulum and microtubules. Proc Natl Acad Sci USA 97: 1101–1106.
Skehel PA, Martin KC, Kandel ER, Bartsch D . (1995). A VAMP-binding protein from Aplysia required for neurotransmitter release. Science 269: 1580–1583.
Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, Daly R et al. (1993). The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 12: 1929–1936.
Sonoyama J, Matsumura I, Ezoe S, Satoh Y, Zhang X, Kataoka Y et al. (2002). Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 277: 8076.
Spirin V, Mirny LA . (2003). Protein complexes and functional modules in molecular networks. Proc Natl Acad Sci USA 100: 12123–12128.
Stuart JR, Gonzalez FH, Kawai H, Yuan Z . (2006). c-Abl interacts with the WAVE2 signaling complex to induce membrane ruffling and cell spreading. J Biol Chem 281: 31290–31297.
Tanaka H, Katoh H, Negishi M . (2006). Pragmin, a novel effector of Rnd2 GTPase, stimulates RhoA activity. J Biol Chem 281: 10355–10364.
Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, Faria D et al. (2009). Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 27: 199–204.
Titz B, Rajagopala SV, Goll J, Häuser R, McKevitt MT, Palzkill T et al. (2008). The binary protein interactome of Treponema pallidum—the syphilis spirochete. PLoS ONE 3: e2292.
Trinkle-Mulcahy L, Boulon S, Lam YW, Urcia R, Boisvert F, Vandermoere F et al. (2008). Identifying specific protein interaction partners using quantitative mass spectrometry and bead proteomes. J Cell Biol 183: 223–239.
Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L et al. (2008). The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28: 3384–3391.
Wong S, Witte ON . (2004). The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22: 247–306.
Yasuda T, Bundo K, Hino A, Honda K, Inoue A, Shirakata M et al. (2007). Dok-1 and Dok-2 are negative regulators of T cell receptor signaling. Int Immunol 19: 487–495.
Yasuda T, Shirakata M, Iwama A, Ishii A, Ebihara Y, Osawa M et al. (2004). Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia. J Exp Med 200: 1681–1687.
Yoon H, Lee J, Randazzo PA . (2008). ARAP1 regulates endocytosis of EGFR. Traffic 9: 2236–2252.
Yu W, Sun X, Clough N, Cobos E, Tao Y, Dai Z . (2008). Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo. Carcinogenesis 29: 1717–1724.
Zimman A, Chen SS, Komisopoulou E, Titz B, Martínez-Pinna R, Kafi A et al. (2010). Activation of aortic endothelial cells by oxidized phospholipids: a phosphoproteomic analysis. J Proteome Res 9: 2812–2824.
Zipfel PA, Bunnell SC, Witherow DS, Gu JJ, Chislock EM, Ring C et al. (2006). Role for the Abi/wave protein complex in T cell receptor-mediated proliferation and cytoskeletal remodeling. Curr Biol 16: 35–46.
Acknowledgements
This work was funded by grants to TGG from the NIH NHGRI (HG002807) and the University of California, Cancer Research Coordinating Committee, and by postdoctoral fellowships of the German Academic Exchange Service to BT and the UCLA Tumor Biology Program USHHS Ruth L Kirschstein Institutional National Research Service Award # T32 CA009056 to SSC. TGG is an Alfred P Sloan Research Fellow. We thank M Negishi, D Korr and T Bürckstümmer for kindly providing plasmids. Flow cytometry was performed in the UCLA Jonsson Comprehensive Cancer Center and Center for AIDS Research Flow Cytometry Core.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Titz, B., Low, T., Komisopoulou, E. et al. The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. Oncogene 29, 5895–5910 (2010). https://doi.org/10.1038/onc.2010.331
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.331
Keywords
This article is cited by
-
Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics
Leukemia (2017)
-
Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis
Leukemia (2017)
-
CRAF R391W is a melanoma driver oncogene
Scientific Reports (2016)
-
LRRK1 is critical in the regulation of B-cell responses and CARMA1-dependent NF-κB activation
Scientific Reports (2016)
-
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
Cell Discovery (2016)
